MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Drugs.com - Clinical Trials' source. Wed, 17 Mar 2010 15:19:10 +0100 http://www.medworm.com/index.php?rid=3372409&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F3gEegfpxlKY%2Famag-pharmaceuticals-inc-announces-data-presentation-national-kidney-foundation-nkf-2010-spring-9014.html LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 16, 2010 - AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that one abstract has been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting being held... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372409 Tue, 16 Mar 2010 15:02:58 +0100 3372409 http://www.medworm.com/index.php?rid=3372410&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FgYbJ-xrY58A%2Fstudy-shows-superior-efficacy-taxus-express-stents-one-year-compared-bare-metal-stents-diabetic-9015.html Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS(R) Liberte(R) Stents in AMI patients NATICK, Mass. and ATLANTA, March 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) today announced results... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372410 Tue, 16 Mar 2010 13:54:33 +0100 3372410 http://www.medworm.com/index.php?rid=3372411&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F9n_IqfIFEy8%2Ficagen-reports-positive-results-ica-105665-patients-photosensitive-epilepsy-9019.html RESEARCH TRIANGLE PARK, N.C., Mar 15, 2010 (GlobeNewswire via COMTEX) -- Icagen, Inc. (Nasdaq:ICGN) today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372411 Tue, 16 Mar 2010 13:40:30 +0100 3372411 http://www.medworm.com/index.php?rid=3372412&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_xTZrxrK3a4%2Fnovartis-international-ag-ch-exploratory-trial-shows-no-incremental-benefit-aliskiren-add-therapy-9016.html · Trial assessed addition of aliskiren to help limit changes to the heart's shape and function in patients after heart attack (post-myocardial infarction)[1] ·  A small numerical reduction in cardiac volume from adding aliskiren to standard... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372412 Tue, 16 Mar 2010 13:40:06 +0100 3372412 http://www.medworm.com/index.php?rid=3372413&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FrNCleStHzgQ%2Fsingle-short-course-tolerx-s-otelixizumab-provides-prolonged-preservation-beta-cell-function-9017.html Four-Year Follow-Up Study of Otelixizumab Published in Diabetologia Is the First Placebo-Controlled Demonstration of Long Term Data CAMBRIDGE, Mass., March 16 /PRNewswire/ -- Tolerx, Inc., today announced the publication in Diabetologia, the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372413 Tue, 16 Mar 2010 13:19:55 +0100 3372413 http://www.medworm.com/index.php?rid=3372414&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6B0vR8ICHR8%2Fcytheris-announces-publication-preclinical-study-journal-immunology-showing-interleukin-7-promotest-9018.html Study indicates rhIL-7 blocks sepsis-induced depletion of CD4 and CD8 T cells, enhances lymphocyte recruitment and prevents sepsis-induced loss in immunity leading to improved survival PARIS--(BUSINESS WIRE)--Mar 16, 2010 - Cytheris SA, a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3372414 Tue, 16 Mar 2010 13:06:02 +0100 3372414 http://www.medworm.com/index.php?rid=3368482&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-8rCdQAIK8I%2Fviron-reports-positive-proof-concept-results-arthritis-vt-346-anti-tnf-therapeutic-9013.html LONDON, ON, March 16 /PRNewswire/ -- Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3368482 Tue, 16 Mar 2010 12:40:30 +0100 3368482 http://www.medworm.com/index.php?rid=3368483&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSYhNCbpG7Ak%2Fintensive-lipitor-therapy-associated-reduced-risk-cardiovascular-events-two-risk-patient-groups-9012.html ATLANTA--(BUSINESS WIRE)--Mar 15, 2010 - Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD)... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3368483 Mon, 15 Mar 2010 20:49:19 +0100 3368483 http://www.medworm.com/index.php?rid=3368484&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F14nBP4rJvc8%2Fportola-pharmaceuticals-merck-announce-phase-2-study-showed-investigational-factor-xa-inhibitor-9010.html ATLANTA--(BUSINESS WIRE)--Mar 15, 2010 - Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3368484 Mon, 15 Mar 2010 19:18:54 +0100 3368484 http://www.medworm.com/index.php?rid=3368485&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FgdxOmCdbC-4%2Falnylam-collaborators-present-new-pre-clinical-research-rnai-therapeutics-targeting-pcsk9-9011.html – Data in Non-Human Primates Show Potent Reductions in LDL Cholesterol Lasting Over One Month After a Single Dose with No Effects on HDL Cholesterol –   CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 15, 2010 - Alnylam Pharmaceuticals,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3368485 Mon, 15 Mar 2010 19:13:11 +0100 3368485 http://www.medworm.com/index.php?rid=3368486&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FE5LPRgxEy_o%2Flandmark-accord-trial-finds-intensive-blood-pressure-combination-lipid-therapies-do-not-reduce-9009.html BETHESDA, Md., March 15, 2010-- Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3368486 Mon, 15 Mar 2010 15:25:44 +0100 3368486 http://www.medworm.com/index.php?rid=3365094&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNcdCMJtrqss%2Fnovartis-international-ag-ch-navigator-shows-valsartan-delayed-progression-type-2-diabetes-risk-9008.html *NAVIGATOR study involved more than 9,000 patients, making it one of the largest and longest global trials to date in pre-diabetic patients * Valsartan-based regimen reduced risk of developing new-onset diabetes by 14%, but did not reduce risk... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3365094 Mon, 15 Mar 2010 12:39:23 +0100 3365094 http://www.medworm.com/index.php?rid=3365095&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fh7rHopdtocM%2Finspire-announces-results-azasite-phase-2-blepharitis-trials-plans-continue-clinical-development-9007.html DURHAM, N.C.--(BUSINESS WIRE)--Mar 15, 2010 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3365095 Mon, 15 Mar 2010 12:09:32 +0100 3365095 http://www.medworm.com/index.php?rid=3365096&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F37OXL8Qu0EE%2Fabbott-statement-accord-lipid-results-support-guidelines-fibrate-9006.html   ATLANTA, March 14 /PRNewswire-FirstCall/ -- Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3365096 Mon, 15 Mar 2010 11:44:14 +0100 3365096 http://www.medworm.com/index.php?rid=3361269&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FrgBD1i3tnV4%2Fasbmr-task-force-reviewing-link-between-fractures-bisphosphonate-therapy-8985.html International Group to Present Findings This Fall; Issues Interim Guidance WASHINGTON--(BUSINESS WIRE)--Mar 11, 2010 - Recent reports suggesting a link between long-term bisphosphonate usage and rare bone fractures have sparked rising concern among... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3361269 Fri, 12 Mar 2010 19:52:43 +0100 3361269 http://www.medworm.com/index.php?rid=3361270&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FAp6MWD4WNGA%2Fpolymedix-presents-pmx-30063-antibiotic-data-8th-world-congress-trauma-shock-inflammation-sepsis-8983.html Session on Bacterial Drug Resistance, Superbugs, and the Need for New Antibiotics   RADNOR, Pa.--(BUSINESS WIRE)--Mar 11, 2010 - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3361270 Fri, 12 Mar 2010 18:36:29 +0100 3361270 http://www.medworm.com/index.php?rid=3361271&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSg-VOlk8Gd8%2Fbaxter-presents-clinical-efficacy-results-phase-iii-study-seasonal-flu-vaccine-8984.html PREFLUCEL Influenza Vaccine shows 78 percent rate of prevention against matching influenza strains   DEERFIELD, Ill.--(BUSINESS WIRE)--Mar 11, 2010 - Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC),... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3361271 Fri, 12 Mar 2010 18:25:41 +0100 3361271 http://www.medworm.com/index.php?rid=3361272&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fjf06DgB0HS4%2Fnovel-stroke-passes-safety-stage-uci-led-clinical-trial-8982.html Sequential-growth-factor therapy holds promise for improving recovery outcomes  Irvine, Calif., March 10, 2010 —A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3361272 Fri, 12 Mar 2010 16:39:42 +0100 3361272 http://www.medworm.com/index.php?rid=3361273&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNeE6oQO9ho8%2Fbiosante-announces-positive-leukemia-vaccine-results-8981.html Johns Hopkins Researchers Say Vaccine Appears to “Mop Up” Leukemia Cells Gleevec Leaves Behind LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Mar 11, 2010 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced positive results of a human... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3361273 Fri, 12 Mar 2010 14:42:45 +0100 3361273 http://www.medworm.com/index.php?rid=3356872&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F96rTAHXxRkU%2Fgenentech-provides-update-phase-iii-study-avastin-men-late-stage-prostate-cancer-8977.html SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 12, 2010 - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356872 Fri, 12 Mar 2010 12:17:17 +0100 3356872 http://www.medworm.com/index.php?rid=3356873&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_co3K9FNFs4%2Ftranzyme-pharma-s-clinical-results-ulimorelin-tzp-101-selected-oral-presentation-distinguished-8978.html RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 12, 2010 - Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356873 Fri, 12 Mar 2010 12:16:52 +0100 3356873 http://www.medworm.com/index.php?rid=3356874&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FF1gRY_s3eNs%2Ftwo-phase-3-trials-sunitinib-commonly-chemotherapies-advanced-breast-cancer-did-not-meet-primary-8979.html Detailed Results to be Presented at Future Medical Meeting NEW YORK--(BUSINESS WIRE)--Mar 11, 2010 - Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356874 Fri, 12 Mar 2010 11:43:07 +0100 3356874 http://www.medworm.com/index.php?rid=3356875&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FVjMAbIwdA20%2Fpfizer-discontinues-phase-3-study-figitumumab-previously-treated-patients-advanced-non-small-cell-8980.html Findings will Contribute to Understanding and Future Study of Figitumumab NEW YORK--(BUSINESS WIRE)--Mar 11, 2010 - Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356875 Fri, 12 Mar 2010 11:42:45 +0100 3356875 http://www.medworm.com/index.php?rid=3356876&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZJegUKzAblE%2Fallon-s-phase-1-trial-broadens-davunetide-s-intranasal-safety-range-8976.html VANCOUVER — Allon Therapeutics Inc. (TSX: NPC) announced today that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide, which began patient enrolment January 28, 2010, has been completed.  The results demonstrated that... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356876 Thu, 11 Mar 2010 20:00:00 +0100 3356876 http://www.medworm.com/index.php?rid=3356877&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FMyboKPWreoo%2Faccess-pharmaceuticals-reports-significant-oral-bioavailability-cobalamin-tm-oral-insulin-8975.html Cobalamin Seen As Broadly Applicable For Oral Delivery Of Many Large Molecule Drugs Now Administered By Injection DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) announced that it has... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3356877 Thu, 11 Mar 2010 19:43:15 +0100 3356877 http://www.medworm.com/index.php?rid=3352479&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FdUKoW1HVBu8%2Fbioalliance-announces-positive-preliminary-results-first-phase-clinical-trial-fentanyl-lauriad-8974.html Sustained systemic absorption means that administration for severe chronic cancer pain can be envisaged   PARIS--(BUSINESS WIRE)--Mar 10, 2010 - Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352479 Wed, 10 Mar 2010 19:49:55 +0100 3352479 http://www.medworm.com/index.php?rid=3352480&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F2F9YgW9oDRI%2Flimerick-biopharma-announces-positive-phase-1a-data-lim-0705-8972.html SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 10, 2010 - Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced positive results of a Phase 1a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352480 Wed, 10 Mar 2010 16:22:23 +0100 3352480 http://www.medworm.com/index.php?rid=3352481&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FjJxdonGZ2Ms%2Fimmunocellular-therapeutics-dendritic-cell-based-vaccine-demonstrates-statistically-significant-8973.html LOS ANGELES--(BUSINESS WIRE)--Mar 10, 2010 - ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352481 Wed, 10 Mar 2010 16:22:21 +0100 3352481 http://www.medworm.com/index.php?rid=3352482&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FzDPUrIKKkTU%2Fresearch-findings-expected-ease-low-neutrophil-counts-cancer-patients-8969.html Multicenter trial led by St. Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients MEMPHIS, Tenn., March 10 /PRNewswire-USNewswire/ -- For patients like 10-year-old Sabrina Jo Spence, new... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352482 Wed, 10 Mar 2010 15:43:30 +0100 3352482 http://www.medworm.com/index.php?rid=3352483&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FvmLRb4QctH0%2Fqlt-announces-phase-ii-clinical-trial-results-development-plans-punctal-plug-delivery-8970.html -- 90-Day Retention Rate of 81% for Latest Punctal Plug Prototype Device -- No Dose Response Seen with Higher Doses in Phase II Clinical Studies -- Expand Development Plans of the Punctal Plug Delivery System in Allergic Conjunctivitis --... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352483 Wed, 10 Mar 2010 15:25:52 +0100 3352483 http://www.medworm.com/index.php?rid=3352484&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FoLV_eI5Qcwk%2Fam-pharma-presents-positive-results-phase-ii-trial-acute-kidney-injury-8971.html AM-Pharma presents positive Phase II results for potential First-In-Class drug AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury at the ISICEM conference in Brussels Alkaline... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3352484 Wed, 10 Mar 2010 15:13:19 +0100 3352484 http://www.medworm.com/index.php?rid=3348793&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fu4KMl99XQF8%2Fmedicine-lower-blood-pressure-significantly-decreases-risk-cardiovascular-stroke-8968.html Study highlights: Medicine to lower blood pressure decreased risk of cardiovascular disease, including stroke, by more than 25 percent among normal weight, overweight and obese patients. Obese patients, who had higher initial blood pressure... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348793 Wed, 10 Mar 2010 14:42:16 +0100 3348793 http://www.medworm.com/index.php?rid=3348794&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F0s1JWHgSUu8%2Facologix-presents-data-cartilage-regeneration-ac-100-56th-annual-meeting-orthopaedic-research-8967.html HAYWARD, Calif., March 6 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348794 Tue, 09 Mar 2010 21:21:44 +0100 3348794 http://www.medworm.com/index.php?rid=3348795&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZFBQFODUF8I%2Fgenomic-health-announces-publication-study-using-oncotype-dx-r-node-negative-node-positive-breast-8966.html REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (NASDAQ:GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348795 Tue, 09 Mar 2010 19:55:55 +0100 3348795 http://www.medworm.com/index.php?rid=3348796&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZA7p27RzZcQ%2Fnew-data-presented-american-burn-association-s-annual-meeting-support-safety-profile-recothrom-8963.html SEATTLE--(BUSINESS WIRE)--Mar 9, 2010 - ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348796 Tue, 09 Mar 2010 19:33:47 +0100 3348796 http://www.medworm.com/index.php?rid=3348797&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fcai8cUz1y7E%2Fmayo-researchers-link-obesity-worse-outcome-patients-being-treated-colon-cancer-8964.html Researchers say that obesity leads to more aggressive colon cancer and that the risk differs between men and women ROCHESTER, Minn.--(BUSINESS WIRE)--Mar 9, 2010 - It's long been known that obesity is linked to increased risk of developing... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348797 Tue, 09 Mar 2010 19:11:28 +0100 3348797 http://www.medworm.com/index.php?rid=3348798&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6meIzmYPY9A%2Fbiomimetic-therapeutics-presents-promising-pre-clinical-sports-medicine-data-2010-ors-meeting-8965.html Data Demonstrates rhPDGF-BB, in Combination with Tissue Specific Matrix Materials, Promotes Healing in Achilles and Rotator Cuff Tears   FRANKLIN, Tenn.--(BUSINESS WIRE)--Mar 9, 2010 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348798 Tue, 09 Mar 2010 19:05:53 +0100 3348798 http://www.medworm.com/index.php?rid=3348799&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FfXoZIg3NbzI%2Finhibitex-present-two-upcoming-conferences-8962.html ATLANTA--(BUSINESS WIRE)--Mar 8, 2010 - Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348799 Tue, 09 Mar 2010 18:34:05 +0100 3348799 http://www.medworm.com/index.php?rid=3348800&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYFh7UUjek6M%2Fwarfarin-users-appear-more-likely-develop-brain-bleeding-following-stroke-8961.html CHICAGO, March 8, 2010-Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3348800 Tue, 09 Mar 2010 14:15:30 +0100 3348800 http://www.medworm.com/index.php?rid=3345078&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FhqjSfVMu2eU%2Finsys-therapeutics-inc-announces-positive-phase-iii-efficacy-trial-results-fentanyl-sublingual-8959.html - Unique delivery method achieves statistical significance in five minutes         PHOENIX, March 09, 2010 /PRNewswire/ -- INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345078 Tue, 09 Mar 2010 13:35:14 +0100 3345078 http://www.medworm.com/index.php?rid=3345079&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FCgSv0PL1PbY%2Fnektar-announces-positive-prelim-data-nktr-102-ovarian-cancer-8960.html SAN CARLOS, Calif., March 8, 2010 -- Nektar Therapeutics (Nasdaq: NKTR) today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345079 Tue, 09 Mar 2010 13:25:58 +0100 3345079 http://www.medworm.com/index.php?rid=3345080&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbSyOq4PGOJU%2Fomthera-pharmaceuticals-inc-closes-6-5m-series-led-sofinnova-partners-advance-epanova-omega-3-8958.html Dyslipidemia Experts Jerry Wisler and Michael Davidson, M.D. Co-Found New Pharmaceutical Company Developing a Prescription Omega 3 Treatment of High Triglycerides NEW YORK--(BUSINESS WIRE)--Mar 8, 2010 - Omthera Pharmaceuticals, Inc., an... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345080 Mon, 08 Mar 2010 20:18:11 +0100 3345080 http://www.medworm.com/index.php?rid=3345081&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FKwTGI9H7uVo%2Fnektar-announces-positive-phase-2-clinical-data-first-stage-nktr-102-study-women-platinum-resistant-8956.html SAN CARLOS, Calif., March 8 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345081 Mon, 08 Mar 2010 19:15:33 +0100 3345081 http://www.medworm.com/index.php?rid=3345082&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FF_Fds8gzl2Q%2Fmillennium-announces-first-clinical-data-tak-700-prostate-molecule-asco-gu-8957.html CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2010 - Millennium: The Takeda Oncology Company today announced the presentation of safety, pharmacokinetic and efficacy data from the Phase I portion of a Phase I/II clinical trial evaluating TAK-700 in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345082 Mon, 08 Mar 2010 18:51:00 +0100 3345082 http://www.medworm.com/index.php?rid=3345083&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6314v0UQ8HM%2Fargos-therapeutics-presents-positive-phase-2-data-arcelis-personalized-immunotherapy-platform-8955.html -Immunotherapy Demonstrates Encouraging Immune and Clinical Responses-   DURHAM, N.C.--(BUSINESS WIRE)--Mar 8, 2010 - Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345083 Mon, 08 Mar 2010 18:05:00 +0100 3345083 http://www.medworm.com/index.php?rid=3345084&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FTfnkxT57oao%2Fnew-imiquimod-formulation-actinic-keratosis-published-jaad-8952.html Study Examining New Short-Course Imiquimod Formulation in Actinic Keratosis published in Journal of the American Academy of Dermatology Imiquimod 3.75% Is Now Available In Pharmacies Across Canada TORONTO, ON, March 8, 2010 – The Journal of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345084 Mon, 08 Mar 2010 16:50:36 +0100 3345084 http://www.medworm.com/index.php?rid=3345085&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_LGE67dTDmM%2Frecentin-did-not-meet-primary-endpoint-horizon-iii-study-metastatic-colorectal-cancer-8953.html This study,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345085 Mon, 08 Mar 2010 14:12:07 +0100 3345085 http://www.medworm.com/index.php?rid=3345086&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FE8MWQXIEplk%2Fgenmab-announces-results-zalutumumab-phase-iii-study-refractory-head-neck-cancer-patients-8954.html Copenhagen, Denmark; March 08, 2010 – Genmab A/S (OMX: GEN) announced today top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who failed standard... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3345086 Mon, 08 Mar 2010 13:59:15 +0100 3345086 http://www.medworm.com/index.php?rid=3337149&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6NmieB088bE%2Fscientists-find-new-prion-damages-brain-arteries-8951.html Study in Mice May Offer Clues for Treating Alzheimer's Disease WHAT: National Institutes of Health (NIH) scientists investigating how prion diseases destroy the brain have observed a new form of the disease in mice that does not cause the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337149 Fri, 05 Mar 2010 20:46:59 +0100 3337149 http://www.medworm.com/index.php?rid=3337150&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FscYqN8HruSg%2Fponiard-pharmaceuticals-presents-positive-survival-data-phase-2-clinical-study-picoplatin-8950.html SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337150 Fri, 05 Mar 2010 20:25:32 +0100 3337150 http://www.medworm.com/index.php?rid=3337151&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FGIOJoCCWNtE%2Fponiard-pharm-presents-positive-survival-data-p2-study-metastatic-prostate-cancer-8949.html Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium SOUTH SAN FRANCISCO, Calif. –... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337151 Fri, 05 Mar 2010 19:06:57 +0100 3337151 http://www.medworm.com/index.php?rid=3337152&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FOq4FLJIsQ-c%2Fcommon-osteoporosis-associated-decrease-risk-breast-cancer-8945.html SEATTLE, March 5 /PRNewswire/ -- Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337152 Fri, 05 Mar 2010 14:36:02 +0100 3337152 http://www.medworm.com/index.php?rid=3337153&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FjyjVbpHdqRQ%2Fresearchers-report-thymosin-beta-4-improves-neurological-function-after-stroke-8946.html Tβ4 Found to Stimulate Oligoprogenitor Cells ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 5, 2010 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced that a research team from the Henry Ford Hospital in Detroit, MI reported... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337153 Fri, 05 Mar 2010 14:31:04 +0100 3337153 http://www.medworm.com/index.php?rid=3337154&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FrdwS9OiChN4%2Fexperimental-vaccine-protects-monkeys-against-chikungunya-8947.html Mosquito-borne virus has infected millions of people in Asia, Africa and Europe GALVESTON, Texas — Imagine a mosquito-borne virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337154 Fri, 05 Mar 2010 14:25:23 +0100 3337154 http://www.medworm.com/index.php?rid=3337155&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FUZilhTxLp2I%2Fopen-label-study-supports-long-term-efficacy-xenazine-tetrabenazine-hd-chorea-8948.html Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea associated with Huntington's disease demonstrated in pivotal study\ DEERFIELD, Ill., March 5, 2010 – Lundbeck Inc. today announced the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337155 Fri, 05 Mar 2010 14:23:09 +0100 3337155 http://www.medworm.com/index.php?rid=3337156&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FmXI9FhOjodk%2Fphase-iii-region-study-shows-pep005-ingenol-mebutate-gel-0-05-may-reduce-pre-cancerous-skin-lesions-8944.html Data Presented at the 68th Annual Meeting of the American Academy of Dermatology PARSIPPANY, N.J., March 5 /PRNewswire/ -- Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3337156 Fri, 05 Mar 2010 13:44:45 +0100 3337156 http://www.medworm.com/index.php?rid=3333550&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fy5JLUm5H00U%2Fadvance-2-study-results-demonstrate-investigational-anticoagulant-apixaban-statistically-superior-8943.html Phase III Data Published in The Lancet also Demonstrate Comparable Rates of Bleeding with Apixaban Versus Enoxaparin PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - Apixaban, an oral anticoagulant being developed by Bristol-Myers... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3333550 Fri, 05 Mar 2010 12:45:23 +0100 3333550 http://www.medworm.com/index.php?rid=3333551&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FifMPcYOnhQw%2Fpresentations-geron-s-telomerase-inhibitor-aacr-special-conference-8942.html Data Shows Activity of Imetelstat Against Cancer Stem Cells MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 2, 2010 - Geron Corporation (Nasdaq:GERN) today announced several presentations at the American Association for Cancer Research (AACR)... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3333551 Thu, 04 Mar 2010 18:53:04 +0100 3333551 http://www.medworm.com/index.php?rid=3333552&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FXwcCrwyRpfM%2Fbeta-blocker-therapy-underused-heart-failure-patients-8941.html New Saint Louis U research suggests reliance on technology rather than drug therapy ST. LOUIS, March 4, 2010 – New Saint Louis University research has found that beta blockers, a class of drugs used to prevent the progression of heart failure... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3333552 Thu, 04 Mar 2010 16:15:59 +0100 3333552 http://www.medworm.com/index.php?rid=3333553&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F7QXcxAlOemM%2Fargos-therapeutics-publishes-positive-immune-response-safety-manufacturing-data-arcelis-hiv-program-8939.html DURHAM, N.C.--(BUSINESS WIRE)--Mar 4, 2010 - Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3333553 Thu, 04 Mar 2010 15:39:23 +0100 3333553 http://www.medworm.com/index.php?rid=3333554&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FAqJTJjRvqfA%2Fnegative-phase-iii-trial-results-latrepirdine-dimebon-8940.html Alzheimer's Association Statement CHICAGO, March 3 /PRNewswire-USNewswire/ -- "The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D.,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3333554 Thu, 04 Mar 2010 15:02:24 +0100 3333554 http://www.medworm.com/index.php?rid=3329488&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNF3o4nh8O_k%2Fstelara-remicade-data-plaque-psoriasis-presented-american-academy-dermatology-aad-meeting-8938.html MIAMI, March 4 /PRNewswire/ -- Data evaluating the efficacy and safety of STELARA(TM) (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329488 Thu, 04 Mar 2010 14:11:35 +0100 3329488 http://www.medworm.com/index.php?rid=3329489&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FFCUDasIxKZE%2Fdendreon-presents-updated-impact-results-confirming-provenge-improves-overall-survival-patients-8937.html -- Data to be Presented at ASCO-GU Annual Symposium -- SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329489 Thu, 04 Mar 2010 13:52:17 +0100 3329489 http://www.medworm.com/index.php?rid=3329490&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FzQ76LLj5lqQ%2Fraptor-pharmaceutical-announces-publication-data-supporting-potential-efficacy-wnttide-tm-triple-8936.html NOVATO, Calif., Mar 4, 2010 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced the publication of data on a proprietary, Mesd (Mesoderm development)-based peptide, also known as... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329490 Thu, 04 Mar 2010 13:12:59 +0100 3329490 http://www.medworm.com/index.php?rid=3329491&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F337LREwnZzY%2Fcabazitaxel-increased-survival-patients-advanced-hormone-refractory-prostate-cancer-8935.html - Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy - - Data from large international Phase 3 study to be presented at the 2010 Genitourinary Cancers Symposium... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329491 Thu, 04 Mar 2010 12:54:30 +0100 3329491 http://www.medworm.com/index.php?rid=3329492&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FIOehIi6E_zI%2Fanavex-comments-failure-pfizer-medivation-s-alzheimer-s-investigational-dimebon-during-phase-3-8934.html GENEVA, SWITZERLAND, March 3 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a statement following today's announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329492 Wed, 03 Mar 2010 21:20:19 +0100 3329492 http://www.medworm.com/index.php?rid=3329493&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FrllJbeABZaI%2Fpatient-age-not-factor-second-line-therapy-lung-cancer-8933.html 'Salvage' therapy just as suitable for NSCLC patients over age 70 as for younger patients Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329493 Wed, 03 Mar 2010 20:10:48 +0100 3329493 http://www.medworm.com/index.php?rid=3329494&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYIXxaM98Szg%2Fhiv-vaccine-strategy-expands-immune-responses-8932.html Mosaic vaccines show promise in reducing the spread of deadly virus LOS ALAMOS, New Mexico, March 3, 2010—Two teams of researchers—including Los Alamos National Laboratory theoretical biologists Bette Korber, Will Fischer, Sydeaka... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329494 Wed, 03 Mar 2010 20:10:21 +0100 3329494 http://www.medworm.com/index.php?rid=3329495&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fb13B-h62QpE%2Fpsivida-reports-presentation-additional-positive-24-month-data-iluvien-phase-3-fame-study-diabetic-8930.html WATERTOWN, Mass.--(BUSINESS WIRE)--Mar 3, 2010 - pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) (FF:PV3), a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329495 Wed, 03 Mar 2010 19:05:41 +0100 3329495 http://www.medworm.com/index.php?rid=3329496&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FuoYnSzA0C1g%2Fptc-therapeutics-genzyme-corporation-announce-preliminary-results-phase-2b-clinical-trial-ataluren-8931.html SOUTH PLAINFIELD, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 3, 2010 - PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329496 Wed, 03 Mar 2010 19:05:36 +0100 3329496 http://www.medworm.com/index.php?rid=3329497&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FoiiusiyRXak%2Fif-you-simvastatin-control-cholesterol-watch-out-infection-says-new-report-8929.html BETHESDA, Md., March 2, 2010-New research published in the Journal of Leukocyte Biology suggests that simvastatin negatively impacts the immune system's ability to clear infection and control inflammation in the presence of bacteria. Simvastatin... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329497 Wed, 03 Mar 2010 16:12:05 +0100 3329497 http://www.medworm.com/index.php?rid=3329498&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FivFXIeartsU%2Fherceptin-tykerb-effective-against-subset-gastric-cancers-8927.html LOS ANGELES, March 3, 2010-A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329498 Wed, 03 Mar 2010 16:00:26 +0100 3329498 http://www.medworm.com/index.php?rid=3329499&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FelXpwXwUwrA%2Fpfizer-medivation-announce-results-two-phase-3-studies-dimebon-latrepirdine-alzheimer-s-clinical-8928.html In CONNECTION Study, Dimebon Does Not Meet Primary and Secondary Efficacy Endpoints Separate Phase 3 Safety Study Demonstrates Dimebon's Tolerability When Used Alone or in Combination with Approved Alzheimer's Disease Medicines Medivation to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3329499 Wed, 03 Mar 2010 15:20:03 +0100 3329499 http://www.medworm.com/index.php?rid=3325329&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYkbg77ixVFg%2Fmerck-reports-results-phase-iii-study-investigational-oral-allergy-immunotherapy-tablet-ait-8924.html Data Presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting NEW ORLEANS--(BUSINESS WIRE)--Mar 2, 2010 - In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325329 Tue, 02 Mar 2010 21:42:16 +0100 3325329 http://www.medworm.com/index.php?rid=3325330&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBOPpT6-aD0A%2Fsurveys-reveal-frequency-prodromal-prior-acute-hereditary-angioedema-attacks-8926.html Warning signs may indicate need for on-demand treatment to achieve better outcomes NEW ORLEANS, March 1 /PRNewswire/ -- Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325330 Tue, 02 Mar 2010 21:17:38 +0100 3325330 http://www.medworm.com/index.php?rid=3325331&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FluroX-2Ir5M%2Fstudy-shows-c1-esterase-inhibitor-concentrate-rapidly-relieves-acute-successive-attacks-hereditary-8925.html Additional data presented at the 2010 AAAAI Annual Meeting confirms long half-life of C1-INH protects HAE patients from rebound attacks NEW ORLEANS, March 1 /PRNewswire/ -- C1-esterase inhibitor (C1-INH) concentrate is an effective,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325331 Tue, 02 Mar 2010 21:17:07 +0100 3325331 http://www.medworm.com/index.php?rid=3325332&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FUUOxIJ_-zvY%2Fpeer-reviewed-articles-further-define-clusterin-role-clusterin-inhibitor-ogx-011-cancer-8923.html BOTHELL, WA and VANCOUVER, March 1 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that two peer-reviewed articles have been published that further elucidate the biological function of clusterin, its role... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325332 Tue, 02 Mar 2010 19:47:33 +0100 3325332 http://www.medworm.com/index.php?rid=3325333&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fh0aXe9pTbxU%2Fgenetic-immunity-presents-dermavir-dna-vaccines-2010-conference-unique-nanomedicine-formulation-8922.html BUDAPEST, Hungary & MCLEAN, Va.--(BUSINESS WIRE)--Mar 2, 2010 - Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's DNA Vaccines 2010 in New Orleans, LA concerning the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325333 Tue, 02 Mar 2010 19:30:12 +0100 3325333 http://www.medworm.com/index.php?rid=3325334&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fo7F0HUU8SsE%2Fdata-two-phase-iii-studies-merck-s-investigational-asthma-presented-american-academy-allergy-asthma-8921.html NEW ORLEANS--(BUSINESS WIRE)--Mar 2, 2010 - Data from two Phase III studies of Merck's investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325334 Tue, 02 Mar 2010 17:14:05 +0100 3325334 http://www.medworm.com/index.php?rid=3325335&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FsZZ7fjLSDHM%2Ficagen-reports-results-phase-ib-pain-study-ica-105665-8920.html RESEARCH TRIANGLE PARK, N.C., Mar 1, 2010 (GlobeNewswire via COMTEX) -- Icagen, Inc. (Nasdaq:ICGN) today reported results of its Phase Ib pain study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325335 Tue, 02 Mar 2010 14:51:29 +0100 3325335 http://www.medworm.com/index.php?rid=3325336&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FtZxpBmzFNhA%2Fhalcygen-pharmaceuticals-successful-outcome-european-clinical-pharmacokinetic-study-comparing-suba-8918.html HalcyGen to begin Marketing Authorisation Application for Regulators in Europe Melbourne Australia, 2nd March 2010 - HalcyGen Pharmaceuticals Limited (ASX: HGN) is pleased to announce that preliminary results from its UK-based... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325336 Tue, 02 Mar 2010 14:41:11 +0100 3325336 http://www.medworm.com/index.php?rid=3325337&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FcUUrWyY7w8Q%2Fkalbitor-ecallantide-data-presented-american-academy-allergy-asthma-immunology-annual-meeting-8919.html - Results of KALBITOR Efficacy for HAE Acute Attacks by Attack Location - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 2, 2010 - Data demonstrating the effectiveness of KALBITOR (ecallantide) to treat hereditary angioedema (HAE) acute attacks by... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3325337 Tue, 02 Mar 2010 14:34:09 +0100 3325337 http://www.medworm.com/index.php?rid=3320372&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FkiAXtaBodxI%2Fneuroimaging-technique-supports-reduction-amyloid-beta-brains-patients-suffering-alzheimer-s-8916.html Phase II Study Published Online in Lancet Neurology DUBLIN--(BUSINESS WIRE)--Mar 1, 2010 - Elan Corporation, plc (NYSE: ELN) today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320372 Mon, 01 Mar 2010 21:17:28 +0100 3320372 http://www.medworm.com/index.php?rid=3320373&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZt_eE2Kw8ec%2Fupdate-scai-statement-crest-study-findings-carotid-stenting-safe-effective-carotid-surgery-patients-8917.html WASHINGTON, Feb. 26 /PRNewswire/ -- Carotid artery stenting, a less invasive alternative to surgery on the carotid artery (carotid endarterectomy), is equally safe and effective for people at risk for stroke as carotid endarterectomy, according to a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320373 Mon, 01 Mar 2010 21:12:13 +0100 3320373 http://www.medworm.com/index.php?rid=3320374&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FDCY1y7rSS9M%2Figpro20-first-20-percent-subcutaneous-immunoglobulin-demonstrates-efficacy-against-infections-while-8913.html KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Mar 1, 2010 - Data presented today suggest that 20 percent liquid formulation, Immune Globulin Subcutaneous (Human) (SCIg), or IgPro20 effectively protects patients with primary immunodeficiencies (PI)... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320374 Mon, 01 Mar 2010 20:20:03 +0100 3320374 http://www.medworm.com/index.php?rid=3320375&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FP4KUVx2c-ds%2Fnew-data-show-igpro20-delivers-highest-available-subcutaneous-ig-concentration-tolerability-8915.html KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Mar 1, 2010 - Data presented today show that IgPro20 the first 20 percent liquid formulation, delivers a higher concentration of treatment, with no trade-off in terms of local tolerability relative to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320375 Mon, 01 Mar 2010 20:19:59 +0100 3320375 http://www.medworm.com/index.php?rid=3320376&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FereXhvIjn_g%2Feuropean-data-suggest-switching-patients-igpro20-may-significantly-reduce-administration-volume-8914.html KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Mar 1, 2010 - Data from a European multicenter (non-IND study) showing that patients with PI who switched to IgPro20 from previously available SCIg formulations achieved comparable IgG trough levels without... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320376 Mon, 01 Mar 2010 20:19:45 +0100 3320376 http://www.medworm.com/index.php?rid=3320377&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FnNlXOHNP_v4%2Ftheratechnologies-announces-publication-jaids-8911.html Theratechnologies Announces Publication of Second Phase 3 Results in JAIDS Montreal, Canada – March 1, 2010 – Theratechnologies (TSX: TH) today announced that the article entitled, “Effects of Tesamorelin, a Growth Hormone-Releasing... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320377 Mon, 01 Mar 2010 19:54:58 +0100 3320377 http://www.medworm.com/index.php?rid=3320378&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F3wFFSsNk5GQ%2Flandmark-head-head-s-f-e-study-comparing-activecare-s-f-t-lovenox-published-journal-bone-joint-8912.html Non-Invasive Compression System Shown To Be No Different In Efficacy Yet Far Safer Than Most Widely Prescribed Drug Therapy for Prevention of VTE OR AKIVA, Israel & WEST HILLS, Calif.--(BUSINESS WIRE)--Mar 1, 2010 - Medical Compression Systems,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320378 Mon, 01 Mar 2010 19:01:26 +0100 3320378 http://www.medworm.com/index.php?rid=3320379&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FqHlEwlsHH6U%2Factelion-pharmaceuticals-ltd-ch-build-3-study-bosentan-idiopathic-pulmonary-fibrosis-does-not-meet-8910.html ALLSCHWIL/BASEL, SWITZERLAND - 01 March 2010 - Actelion Ltd (SIX: ATLN) today announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3320379 Mon, 01 Mar 2010 14:25:28 +0100 3320379 http://www.medworm.com/index.php?rid=3313498&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FuWWxBuFzpuU%2Fresearchers-report-novel-biological-properties-fragments-thymosin-beta-4-8909.html BETHESDA, Md.--(BUSINESS WIRE)--Feb 26, 2010 - RegeneRx Biopharmaceuticals Inc.REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that a university research team has published an article ahead of print in FASEB Journal, a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3313498 Fri, 26 Feb 2010 18:58:32 +0100 3313498 http://www.medworm.com/index.php?rid=3313499&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FtktEDc9oEvQ%2Fsynta-presents-sta-9090-nsclc-data-iaslc-10th-annual-targeted-therapies-lung-cancer-meeting-8908.html - STA-9090 shows activity against EGFR T790M resistance mutation - - Simultaneously inhibits MET, a key mechanism of resistance, and EGFR - LEXINGTON, Mass.--(BUSINESS WIRE)--Feb 26, 2010 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3313499 Fri, 26 Feb 2010 16:03:30 +0100 3313499 http://www.medworm.com/index.php?rid=3313500&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FmW2hlLuClWk%2Fnew-data-demonstrate-early-combination-enbrel-etanercept-methotrexate-can-prevent-rheumatoid-8907.html Feb. 26, 2010: New data from the COMET trial, published today in Arthritis & Rheumatism,demonstrate that combination therapy with etanercept and methotrexate over two years achieved radiographic remission (i) in 90 per cent of evaluable... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3313500 Fri, 26 Feb 2010 15:42:20 +0100 3313500 http://www.medworm.com/index.php?rid=3309621&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FC5mKqn1kJqk%2Fcardiologists-comment-aspirin-versus-resveratrol-8906.html FT. LEE, N.J., Feb. 26 /PRNewswire/ -- With the realization that half of the people experiencing a sudden mortal heart attack were taking aspirin on the day of their demise, and the fact that higher-than-recommended doses of aspirin are needed to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309621 Fri, 26 Feb 2010 13:35:25 +0100 3309621 http://www.medworm.com/index.php?rid=3309622&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FOPujzIo6jyo%2Fcopaxone-15-year-study-multiple-sclerosis-patients-demonstrates-robust-long-term-efficacy-safety-8905.html More than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years The majority of patients experienced either stable or improved disability rates, as well as a 78 percent... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309622 Thu, 25 Feb 2010 20:40:44 +0100 3309622 http://www.medworm.com/index.php?rid=3309623&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSc8qAsDi6QY%2Fh-lundbeck-s-dk-data-post-hoc-analysis-using-desmoteplase-ischaemic-stroke-presented-international-8899.html H. Lundbeck A/S (Lundbeck) today announced that data presented at the International Stroke Conference (ISC) in San Antonio, Texas showed very supportive data for desmoteplase. Post hoc analysis of data from the clinical phase III study, DIAS 2,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309623 Thu, 25 Feb 2010 17:16:58 +0100 3309623 http://www.medworm.com/index.php?rid=3309624&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FDjC-qOIPalw%2Fgenentech-announces-positive-results-avastin-phase-iii-study-women-advanced-ovarian-cancer-8900.html First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint       SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 25, 2010 - Genentech, Inc., a wholly owned member of the Roche... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309624 Thu, 25 Feb 2010 14:06:07 +0100 3309624 http://www.medworm.com/index.php?rid=3309625&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FS8uPAdLU6Gc%2Fana598-demonstrates-73-cevr-combination-interferon-ribavirin-8901.html No Viral Rebound Observed During 12 Weeks of ANA598 Dosing Positive Safety Data with AE Profile Comparable to Control Group Company to Review Data During Q4 Conference Call at 5:00 PM EST Today SAN DIEGO, Feb. 24 /PRNewswire-FirstCall/ --... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309625 Wed, 24 Feb 2010 21:25:24 +0100 3309625 http://www.medworm.com/index.php?rid=3309626&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FcBwG7S-_KfE%2Fnovelos-therapeutics-pivotal-phase-3-lung-cancer-trial-does-not-meet-primary-survival-endpoint-8902.html Detailed Trial Results Expected in 2010 NEWTON, Mass.--(BUSINESS WIRE)--Feb 24, 2010 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309626 Wed, 24 Feb 2010 15:35:19 +0100 3309626 http://www.medworm.com/index.php?rid=3309627&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FQ2vN6B7gDu8%2Fdata-show-valortim-anthrax-anti-toxin-may-augment-immune-s-ability-destroy-anthrax-bacteria-8903.html New Valortim(R) Data Presented at the 8th Annual ASM Biodefense and Emerging Diseases Research Meeting ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309627 Wed, 24 Feb 2010 14:15:16 +0100 3309627 http://www.medworm.com/index.php?rid=3309628&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FCfkzixXwnPY%2Fpublication-vical-s-h5n1-results-paves-way-h1n1-clinical-trial-8904.html SAN DIEGO, Feb. 24, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication in the online edition of Vaccine1 detailed data from two Phase 1 trials of the company's Vaxfectin®-adjuvanted DNA vaccines for H5N1... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3309628 Wed, 24 Feb 2010 13:53:54 +0100 3309628 http://www.medworm.com/index.php?rid=3300394&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fng1LDmk6YU4%2Fstudy-showed-sculptra-aesthetic-effectively-corrects-nasolabial-folds-other-facial-wrinkles-8898.html New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months BRIDGEWATER, N.J., Feb. 23 /PRNewswire-FirstCall/ -- Results published in today's online issue of the Journal of American Academy of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3300394 Tue, 23 Feb 2010 18:38:16 +0100 3300394 http://www.medworm.com/index.php?rid=3300395&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSNcpxpecN_Q%2Fphase-iii-study-avastin-plus-chemotherapy-advanced-stomach-cancer-did-not-meet-primary-endpoint-8897.html SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 23, 2010 - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3300395 Tue, 23 Feb 2010 14:25:21 +0100 3300395 http://www.medworm.com/index.php?rid=3296746&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYEpwixxU5B0%2Fbiosante-pharmaceuticals-reports-positive-libigel-safety-data-phase-iii-program-8896.html LibiGel Phase III Safety Study to Continue Under Current FDA-Agreed Protocol Based On Second Unblinded Data Review by Independent Data Monitoring Committee (DMC) LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 22, 2010 - BioSante Pharmaceuticals, Inc.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3296746 Mon, 22 Feb 2010 20:07:10 +0100 3296746 http://www.medworm.com/index.php?rid=3296747&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYGFM0N0j0Uc%2Fgalderma-announces-positive-results-study-evaluating-regimen-epiduo-gel-doxycycline-100mg-patients-8895.html –Results Could Help Redefine Acne Treatment Regimens and Validate Established Consensus Guidelines– Fort Worth, TX – February X, 2009 – Results from the ACCESS study found that the addition of Epiduo® (adapalene... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3296747 Mon, 22 Feb 2010 18:57:21 +0100 3296747 http://www.medworm.com/index.php?rid=3296748&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F8HxhDC8cmMY%2Fadamas-pharmaceuticals-announces-vitro-data-demonstrating-tcad-therapy-more-potent-than-double-8893.html EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3296748 Mon, 22 Feb 2010 17:13:19 +0100 3296748 http://www.medworm.com/index.php?rid=3296749&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbNit3UeEb3Y%2Fcel-sci-study-shows-cel-2000-vaccine-blocks-progression-rheumatoid-arthritis-8894.html Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3296749 Mon, 22 Feb 2010 17:13:12 +0100 3296749 http://www.medworm.com/index.php?rid=3293262&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fi7Da-bNIa8w%2Favosentan-reduces-proteinuria-but-causes-serious-8892.html Lower Doses May Benefit Kidney Disease Patients without the Risks Washington, DC (February 16, 2010) — The drug avosentan substantially reduces urinary protein loss in people with type 2 diabetes and kidney disease, but the drug causes serious... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3293262 Mon, 22 Feb 2010 13:11:11 +0100 3293262 http://www.medworm.com/index.php?rid=3289797&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FElbXsJOC4xY%2Fvirxsys-announces-croi-promising-results-hiv-vaccine-study-8891.html Lentiviral vector-based vaccine achieved significant control of viral load in monkeys GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb 19, 2010 - VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3289797 Fri, 19 Feb 2010 20:50:10 +0100 3289797 http://www.medworm.com/index.php?rid=3286080&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fl0GS7zhndI0%2Fpharmacokinetic-pharmacodynamic-data-support-further-development-tobira-s-next-generation-ccr5-8890.html PK/PD Data Show Strong Correlation between TBR-652 Drug Exposure and Potent Antiviral Activity SAN FRANCISCO, Feb. 17 /PRNewswire/ -- Pharmacokinetic/pharmacodynamic (PK/PD) data for TBR-652, which is being developed by Tobira Therapeutics for the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286080 Fri, 19 Feb 2010 13:10:53 +0100 3286080 http://www.medworm.com/index.php?rid=3286081&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FPUGcvttErlI%2Fnew-study-compares-efficacy-safety-once-daily-versus-twice-daily-prezista-r-regimen-experienced-8889.html SAN FRANCISCO, Feb. 17 /PRNewswire/ -- In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg)... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286081 Fri, 19 Feb 2010 13:10:16 +0100 3286081 http://www.medworm.com/index.php?rid=3286082&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FgmNrePL3d8c%2Fpreliminary-data-roche-athena-cervical-cancer-trial-support-value-human-papillomavirus-genotyping-8888.html MONTE CARLO, Monaco, Feb. 18 /PRNewswire-FirstCall/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286082 Fri, 19 Feb 2010 13:05:10 +0100 3286082 http://www.medworm.com/index.php?rid=3286083&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FStshyEK0k2A%2Fnovavax-presents-positive-clinical-results-world-health-organization-conference-geneva-switzerland-8887.html - Positive Clinical Results from Pivotal Study of H1N1 Virus-Like Particle (VLP) Pandemic Influenza Vaccine in Mexico - Immunogenicity responses at all dose levels meet U.S. and European regulatory authorities recommended criteria for seroconversion... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286083 Fri, 19 Feb 2010 13:00:14 +0100 3286083 http://www.medworm.com/index.php?rid=3286084&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FUPSnQvQIJFU%2Fbiosante-pharmaceuticals-inc-present-libigel-clinical-update-isswsh-conference-8886.html LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Feb 18, 2010 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women's Sexual Health (ISSWSH),... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286084 Thu, 18 Feb 2010 21:00:04 +0100 3286084 http://www.medworm.com/index.php?rid=3286085&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWLu4aXZiBls%2Fgeovax-labs-inc-reports-data-prototype-adjuvant-supplemented-hiv-vaccine-tested-preclinical-animal-8885.html Results From Study Using Non-human Primates Indicate 70% Level of Protection From Infection Presentation Made at Conference on Retroviruses and Opportunistic Infections ATLANTA, Feb. 18 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286085 Thu, 18 Feb 2010 20:45:06 +0100 3286085 http://www.medworm.com/index.php?rid=3286086&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FJdgQjLZj3ls%2Fnew-pain-management-approaches-reduce-pain-speed-recovery-knee-hip-replacement-8884.html ROCHESTER, Minn.--(BUSINESS WIRE)--Feb 17, 2010 - Patients undergoing knee or hip replacements recover more quickly when treated with targeted pain-blocking medications that may eliminate the need for general anesthesia during surgery and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286086 Thu, 18 Feb 2010 19:47:31 +0100 3286086 http://www.medworm.com/index.php?rid=3286087&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FpnM0sHS8g-0%2Fvegf-trap-eye-shows-positive-results-phase-2-study-patients-diabetic-macular-edema-8883.html - Statistically significant improvement in vision achieved over 24 weeks - Results to be presented at Angiogenesis 2010: Clinical Trials meeting in Miami, Florida on February 20, 2010 TARRYTOWN, N.Y. and LEVERKUSEN, Germany, Feb.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286087 Thu, 18 Feb 2010 15:02:11 +0100 3286087 http://www.medworm.com/index.php?rid=3286088&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZqujH14FxOY%2Frelease-vari-findings-may-help-patients-deadly-kidney-cancer-8882.html Researchers are able to predict and reverse resistance to a commonly used treatment Grand Rapids, Mich. (Feb. 17, 2010) – Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3286088 Thu, 18 Feb 2010 13:01:13 +0100 3286088 http://www.medworm.com/index.php?rid=3281817&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fxm3e4iQxVJI%2Ftobira-s-next-generation-once-daily-ccr5-receptor-antagonist-demonstrates-efficacy-safety-8880.html Phase II Data Presented at Conference of Retroviruses and Opportunistic Infections Support Further Development of TBR-652 SAN FRANCISCO, Feb. 17 /PRNewswire/ -- The first-ever-reported Phase II data for TBR-652, which is being developed by... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3281817 Wed, 17 Feb 2010 20:35:35 +0100 3281817 http://www.medworm.com/index.php?rid=3281818&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWM1bzc01BFo%2Fgilead-s-single-tablet-quad-regimen-hiv-achieves-rate-virologic-suppression-phase-ii-study-8881.html Second Phase II Study Supports GS 9350 (Cobicistat) as a Boosting Agent FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb 17, 2010 - Gilead Sciences, Inc. (Nasdaq:GILD) announced Phase II clinical trial results today showing that its investigational... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3281818 Wed, 17 Feb 2010 20:01:29 +0100 3281818 http://www.medworm.com/index.php?rid=3281819&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fd3wu3MTVZbE%2Fstatins-increase-risk-diabetes-but-absolute-risk-low-especially-compared-reduction-coronary-events-8879.html NEW YORK, Feb. 16, 2010 -New research based on a meta-analysis of 13 statin trials has shown that use of statins increases the risk of developing type 2 diabetes by 9%. However, the absolute risk is low, especially when compared with the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3281819 Wed, 17 Feb 2010 15:35:07 +0100 3281819 http://www.medworm.com/index.php?rid=3281820&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FMPK5bvY98h4%2Fphase-iii-data-merck-s-gardasil-efficacious-against-anal-caused-hpv-6-11-16-18-8878.html Investigational Data Also Presented on Efficacy Against HPV 6,11,16 and 18 -Related Persistent Infection, CIN and EGL in Women Aged 24 Through 45 Naïve to the Relevant HPV Type WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 17, 2010 - Merck &... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3281820 Wed, 17 Feb 2010 14:16:55 +0100 3281820 http://www.medworm.com/index.php?rid=3278195&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FlguS76RB4Ao%2Fleading-u-s-dermatologist-reports-positive-data-artefill-r-8876.html Dr. Christopher Zachary Discusses Interim Data from Artefill Five-Year Safety and Patient Satisfaction Study at the Hawaii Dermatology Seminar SAN DIEGO, Feb. 16 /PRNewswire/ -- Suneva Medical, a privately-held aesthetic medical device company,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278195 Wed, 17 Feb 2010 13:31:29 +0100 3278195 http://www.medworm.com/index.php?rid=3278196&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F5WXCqY8Bi6o%2Fmigraine-more-common-women-ms-8877.html ST. PAUL, Minn., Feb. 16 /PRNewswire-USNewswire/ -- Migraine is seen more frequently in women with multiple sclerosis (MS) than those without, according to a study released today that will be presented at the American Academy of Neurology's 62nd... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278196 Wed, 17 Feb 2010 13:26:25 +0100 3278196 http://www.medworm.com/index.php?rid=3278197&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F68oQI4nZios%2Fgardasil-helps-prevent-anal-cancer-men-showed-new-study-8873.html KIRKLAND, QC, Feb. 17 /CNW Telbec/ - In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278197 Wed, 17 Feb 2010 13:04:46 +0100 3278197 http://www.medworm.com/index.php?rid=3278198&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FE6uiBq3WxoI%2Fpharming-s-c1-inhibitor-product-potentially-effective-reducing-complications-following-8874.html Pharming’s C1 Inhibitor Product Potentially Effective In Reducing Complications Following Transplantation Leiden, The Netherlands, February 17, 2010. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278198 Wed, 17 Feb 2010 12:59:19 +0100 3278198 http://www.medworm.com/index.php?rid=3278199&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FCg0pZRl8XBc%2Fachillion-announces-positive-96-week-data-elvucitabine-17th-annual-conference-retroviruses-8875.html NEW HAVEN, Conn., Feb 17, 2010 (GlobeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278199 Wed, 17 Feb 2010 12:57:39 +0100 3278199 http://www.medworm.com/index.php?rid=3278200&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FiNBVnTPUTho%2Fcannabis-science-announces-preliminary-results-survey-cannabis-veterans-others-post-traumatic-8872.html COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Feb 16, 2010 - Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is reviewing interim results of its survey from over 1400 people, US military veterans and others who... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278200 Tue, 16 Feb 2010 21:20:20 +0100 3278200 http://www.medworm.com/index.php?rid=3278201&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBU3H-PUgdM4%2Fwhi-study-short-term-heart-risks-combination-hormone-therapy-postmenopausal-women-8871.html BETHESDA, Md., Feb. 15, 2010--New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women.  Researchers report a trend toward an increased... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278201 Tue, 16 Feb 2010 20:35:36 +0100 3278201 http://www.medworm.com/index.php?rid=3278202&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FsMNWLc7nRqk%2Fidera-pharmaceuticals-presents-preclinical-hyperlipidemia-data-toll-like-receptor-antagonist-8870.html CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 14, 2010 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278202 Tue, 16 Feb 2010 19:39:06 +0100 3278202 http://www.medworm.com/index.php?rid=3278203&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FlED_nP-aKKk%2Falkermes-announces-positive-results-phase-1-study-new-candidate-opioid-induced-constipation-8868.html - ALKS 37 Targets Gastrointestinal Track with Limited Systemic Exposure-   - Company Plans to Initiate Additional Clinical Studies in First Half of Calendar 2010 -   WALTHAM, Mass.--(BUSINESS WIRE)--Feb 16, 2010 - Alkermes, Inc. (NASDAQ:... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278203 Tue, 16 Feb 2010 19:34:07 +0100 3278203 http://www.medworm.com/index.php?rid=3278204&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FlrZDyk5vIh8%2Fdaclizumab-shows-potential-new-immunoregulatory-approach-treating-multiple-sclerosis-according-data-8869.html Daclizumab Combined with Interferon Beta Reduced MS Lesion Formation 72 Percent More than Interferon Beta Alone Cambridge, Mass. and Redwood City, Calif. – February 16, 2010 – Biogen Idec (NASDAQ: BIIB) and Facet Biotech Corporation... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3278204 Tue, 16 Feb 2010 19:12:17 +0100 3278204 http://www.medworm.com/index.php?rid=3268604&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F2xeobEr0mno%2Fshire-presents-positive-efficacy-safety-data-velaglucerase-alfa-naive-patients-type-1-gaucher-8866.html CAMBRIDGE, Massachusetts, February 11/PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3268604 Fri, 12 Feb 2010 20:52:26 +0100 3268604 http://www.medworm.com/index.php?rid=3268605&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FGSttn7RTeBI%2Famicus-therapeutics-presents-positive-data-update-phase-2-extension-study-amigal-fabry-8867.html Company also presents encouraging preclinical data for Chaperone and ERT Combination Therapy and Parkinson's disease programs CRANBURY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (NASDAQ:FOLD) announced today additional positive... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3268605 Fri, 12 Feb 2010 20:38:33 +0100 3268605 http://www.medworm.com/index.php?rid=3268606&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fww95fSMS4MI%2Fcircassia-achieves-positive-phase-ii-clinical-results-ragweed-allergy-t-cell-vaccine-8864.html Results Mark Third Successful Phase II Study With ToleroMune(R) T-Cell Vaccines OXFORD, England, February 12/PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3268606 Fri, 12 Feb 2010 16:44:31 +0100 3268606 http://www.medworm.com/index.php?rid=3268607&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6pTkhZfIxxs%2Fym-biosciences-presents-cyt387-cyt997-data-international-cancer-conference-8865.html MISSISSAUGA, ON, Feb. 11 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3268607 Fri, 12 Feb 2010 15:56:17 +0100 3268607 http://www.medworm.com/index.php?rid=3268608&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F4IYwb9uzNwk%2Fhelix-biopharma-announces-positive-interim-results-ongoing-phase-ii-pharmacokinetic-clinical-study-8863.html AURORA, Ontario, Feb. 12 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; Pink Sheets: HXBPF) today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3268608 Fri, 12 Feb 2010 15:37:46 +0100 3268608 http://www.medworm.com/index.php?rid=3265146&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FJ-s31HBzvFU%2Fintercell-phase-data-pneumococcus-vaccine-candidate-8861.html Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae » Initial results from a first?in?man Phase I study indicate safety and immunogenicity of the Streptococcus pneumoniae... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265146 Fri, 12 Feb 2010 13:32:17 +0100 3265146 http://www.medworm.com/index.php?rid=3265147&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FC9HcARsVXBk%2Fpopular-antidepressant-blocks-beneficial-tamoxifen-breast-cancer-8862.html Research: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study) http://www.bmj.com/cgi/doi/10.1136/bmj.c693 (Editorial: Interaction of serotonin reuptake inhibitors... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265147 Fri, 12 Feb 2010 13:08:21 +0100 3265147 http://www.medworm.com/index.php?rid=3265148&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FnjmCxCrBe8s%2Fintercell-obtains-results-first-phase-investigational-vaccine-study-streptococcus-pneumoniae-8859.html » Initial results from a first-in-man Phase I study indicate safety and immunogenicity of the Streptococcus pneumoniae vaccine candidate Vienna (Austria), February 11, 2010 – Intercell AG (VSE: “ICLL”) today announced results... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265148 Thu, 11 Feb 2010 21:35:04 +0100 3265148 http://www.medworm.com/index.php?rid=3265149&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fhxw4PTxMnko%2Fprotalix-presents-additional-phase-iii-data-taliglucerase-alfa-world-symposium-8860.html CARMIEL, Israel, Feb. 11 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265149 Thu, 11 Feb 2010 20:21:59 +0100 3265149 http://www.medworm.com/index.php?rid=3265150&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FykrSkKj8Xro%2Fhistone-modification-patterns-predict-prognosis-response-pancreatic-cancer-8858.html Study by UCLA Researchers and Collaborators Demonstrates that Cellular Histone Modification Patterns Predict Prognosis and Treatment Response in Pancreatic Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--PrognosDx Health, Inc. announced today that in an... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265150 Thu, 11 Feb 2010 19:50:58 +0100 3265150 http://www.medworm.com/index.php?rid=3265151&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FgIHAc6P5wak%2Fbiodel-present-results-viaject-phase-3-studies-advanced-technologies-treatments-diabetes-conference-8857.html DANBURY, Conn.--(BUSINESS WIRE)--Feb 11, 2010 - Biodel, Inc. (Nasdaq: BIOD) announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company's two Phase 3 studies with VIAject® ultra-rapid-acting... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265151 Thu, 11 Feb 2010 19:13:13 +0100 3265151 http://www.medworm.com/index.php?rid=3265152&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZp5tCwStBUw%2Ftwo-year-data-phase-2-trial-genzyme-gaucher-oral-compound-suggest-continued-improvement-across-all-8856.html CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2010 - Genzyme Corporation (NASDAQ: GENZ) announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265152 Thu, 11 Feb 2010 18:06:36 +0100 3265152 http://www.medworm.com/index.php?rid=3265153&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F1bKdudX6Mwg%2Fthird-party-reexamination-javelin-pharmaceuticals-phase-iii-trial-data-ereska-intranasal-ketamine-8855.html Company Plans Meeting with FDA to Discuss Next Steps CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2010 - Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV - News) today announced that a reexamination conducted by a third party of pain score measurements... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3265153 Thu, 11 Feb 2010 17:10:34 +0100 3265153 http://www.medworm.com/index.php?rid=3261119&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fo8kOdSxVVTQ%2Famerican-heart-association-rapid-access-journal-report-study-finds-racial-gaps-continue-heart-8854.html   Go Red For Women study reports current awareness and trends since 1997 Study highlights - Minority women's awareness remains behind that of white women. - Only about half of women were aware of heart attack warning signs or said they would... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3261119 Wed, 10 Feb 2010 19:57:51 +0100 3261119 http://www.medworm.com/index.php?rid=3261120&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBxrzHoYCwL0%2Fraptor-pharmaceutical-corp-present-cystinosis-research-lysosomal-network-s-2010-world-symposium-8852.html Forms European Subsidiary, Raptor Pharmaceuticals Europe BV NOVATO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (NASDAQ:RPTP) , today announced the presentation of cystinosis data at the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3261120 Wed, 10 Feb 2010 15:54:57 +0100 3261120 http://www.medworm.com/index.php?rid=3261121&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FMdAJOKA5FjY%2Fportola-pharmaceuticals-announces-late-breaker-presentation-betrixaban-american-college-cardiology-8853.html   SOUTH SAN FRANCISCO, Calif., Feb. 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that results from its Phase 2 EXPLORE-Xa clinical trial of betrixaban, an investigational oral direct Factor Xa inhibitor anticoagulant, will... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3261121 Wed, 10 Feb 2010 15:54:23 +0100 3261121 http://www.medworm.com/index.php?rid=3261122&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fxg1bTvs9miU%2Famira-pharmaceuticals-announces-efficacy-lpa1-antagonist-preclinical-model-scleroderma-8851.html     SAN DIEGO, Feb. 10 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3261122 Wed, 10 Feb 2010 15:35:11 +0100 3261122 http://www.medworm.com/index.php?rid=3261123&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F7zhfMwnpw6k%2Fprognosdx-health-announces-publication-novel-epigenetic-study-journal-clinical-oncology-8850.html Study by UCLA Researchers and Collaborators Demonstrates that Cellular Histone Modification Patterns Predict Prognosis and Treatment Response in Pancreatic Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 10, 2010 - PrognosDx Health, Inc. announced... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=3261123 Wed, 10 Feb 2010 14:34:37 +0100 3261123